Automate Your Wheel Strategy on ERAS
With Tiblio's Option Bot, you can configure your own wheel strategy including ERAS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Erasca Stock Surges 42% in a Week: Here's What You Should Know
Published: January 16, 2026 by: Zacks Investment Research
Sentiment: Positive
ERAS stock jumps 42% in a week after early phase I solid tumors study data for ERAS-0015 shows encouraging responses, favourable safety and faster-than-expected enrollment.
Read More
What's Going With Cancer Biotech Erasca Stock On Thursday?
Published: January 08, 2026 by: Benzinga
Sentiment: Negative
Erasca Inc. (NASDAQ: ERAS) shares on Wednesday jumped close to 60% to $6.12. On Thursday, the stock fell as low as $4.33.
Read More
Erasca to Present at the 8th Annual Evercore Healthcare Conference
Published: November 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 8th Annual Evercore Healthcare Conference being held at the Loews Coral Gables Hotel in Coral Gables, FL. Management will participate in a fireside chat on Wednesday, December 3, 2025, at 10:25 am Eastern Time and will also participate in one-on-one investor meetings.
Read More
Erasca, Inc.: Carving A Different Niche In RAS Signaling
Published: April 25, 2025 by: Seeking Alpha
Sentiment: Positive
Erasca, Inc. focuses on developing novel targeted therapies for solid tumors, particularly through the RAS/MAP kinase pathway, with a promising yet early-stage pipeline. The company's lead program, naporafenib, shows preliminary efficacy in NRAS-mutant melanoma, with key phase 3 data expected in 2025. Financially stable with a cash runway into at least 2027, Erasca can advance its pipeline without immediate funding concerns, mitigating dilution risk.
Read More
About Erasca, Inc. (ERAS)
- IPO Date 2021-07-16
- Website https://www.erasca.com
- Industry Biotechnology
- CEO Jonathan E. Lim
- Employees 103